Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes...

Area of Science:

• Neuro-oncology
• Molecular biology
• Genomics

Background:

• Meningiomas are tumors arising from the meninges.
• World Health Organization (WHO) grading classifies meningiomas into I, II, and III based on malignancy.
• Understanding gene expression differences across grades is crucial for prognosis.

Purpose of the Study:

• To identify gene expression profiles associated with different World Health Organization (WHO) malignancy grades of human meningiomas.
• To explore correlations between gene expression, genomic aberrations, and tumor progression.

Main Methods:

• Analysis of gene expression in 30 meningioma tumors (13 grade I, 12 grade II, 5 grade III) using cDNA-microarray technology (2,600 genes).
• Receiver operator curve (ROC) analysis to identify differentially expressed genes.
• Comparative genomic hybridization (CGH) to detect genomic aberrations.

Main Results:

• Identified 37 downregulated and 27 upregulated genes in atypical and anaplastic meningiomas compared to benign ones.
• Anaplastic meningiomas distinguished from benign by differential expression of cell cycle and proliferation genes.
• Losses on chromosomes 10 and 14 correlated with distinct expression profiles, including activation of insulin-like growth factor (IGF) and wingless (WNT) pathways.

Conclusions:

• Microarray-based expression profiling reveals novel candidate genes and pathways involved in meningioma progression.
• Specific gene expression patterns are associated with higher-grade meningiomas.
• Genomic aberrations influence gene expression profiles, potentially driving tumor aggressiveness.